Metastatic Renal Cell Carcinoma is an indication for drug development with over 130 pipeline drugs currently active. According to GlobalData, preregistered drugs for Metastatic Renal Cell Carcinoma have a 90.48% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Metastatic Renal Cell Carcinoma compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Metastatic Renal Cell Carcinoma overview
Metastatic Renal Cell Carcinoma (mRCC) refers to advanced kidney cancer where cancer cells originating in the kidneys have spread to other parts of the body. Renal cell carcinoma (RCC) is the most common type of kidney cancer. In metastatic cases, cancer cells may spread to distant organs, such as the lungs, bones, or liver, and potentially lymph nodes. Symptoms may include weight loss, fatigue, pain, and blood in the urine. Diagnosis involves imaging studies like CT scans, MRIs, and sometimes biopsy for confirmation. Treatment for metastatic renal cell carcinoma often includes targeted therapies, immunotherapy, and occasionally surgery or radiation to manage symptoms. The choice of treatment depends on the extent of metastasis, the overall health of the patient, and specific characteristics of the cancer. Regular monitoring and a collaborative, multidisciplinary approach are essential for managing metastatic renal cell carcinoma effectively.
For a complete picture of PTSR and LoA scores for drugs in Metastatic Renal Cell Carcinoma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
